Grenada vs Jordan: Tuberculosis patients living with HIV receiving antiretroviral therapy
Grenada
0 patients
in 2021
Jordan
0 patients
in 2021
Grenada rank
141st
Jordan rank
141st
Tuberculosis patients living with HIV receiving antiretroviral therapy over time
- Grenada
- Jordan
How they compare
Grenada currently reports 0 patients against 0 patients in Jordan, a difference of 0 patients.
The two have swapped places 8 times across 14 shared years of data; in 2003 it was Jordan ahead.
Grenada ranks 141st and Jordan ranks 141st of 183 countries.
Across the 3 decades both report, Grenada averaged higher in 1 and Jordan in 1.
Head to head by decade
| Decade | Grenada | Jordan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.6 patients | 0.2 patients | 0.4 patients | Grenada |
| 2010s | 0.5714 patients | 0.7143 patients | 0.1429 patients | Jordan |
| 2020s | 0 patients | 0 patients | 0 patients | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients living with hiv receiving antiretroviral therapy, Grenada or Jordan?
- Grenada, at 0 patients against 0 patients in Jordan as of 2021.
- What is the difference in tuberculosis patients living with hiv receiving antiretroviral therapy between Grenada and Jordan?
- 0 patients, with Grenada ahead.
- How many years of comparable data are there for Grenada and Jordan?
- 14 years are reported by both, from 2003 to 2021.
- How do Grenada and Jordan rank globally for tuberculosis patients living with hiv receiving antiretroviral therapy?
- Grenada ranks 141st and Jordan ranks 141st of 183 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of tuberculosis patients who are living with HIV and receiving antiretroviral therapy.